US: FDA revokes emergency use of Hydroxychloroquine and Chloroquine
U.S. Food and Drug Administration (FDA) has revoked emergency use authorization for the drugs Hydroxychloroquine and Chloroquine for the treatment of COVID-19 patients after concluding that they may not be effective to cure the virus infections.
- The Food and Drug Administration (FDA) has said its decision is based on new information, including clinical trial data results, that have led it to conclude that the drugs may not be effective to treat COVID-19 and that its potential benefits for such use do not outweigh its known and potential risks.
- FDA Chief Scientist Denise Hinton, in a letter dated 15th of June to Gary Disbrow of Biomedical Advanced Research and Development Authority (BARDA), said as of the date, the oral formulations of Hydroxychloroquine (HCQ) and Chloroquine (CQ) are no longer authorized by the FDA to treat COVID-19. She said that the FDA now believes that the suggested dosing regimens for CQ and HCQ are unlikely to produce an antiviral effect.
- The FDA said that additional clinical trials continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19, we determined the emergency use authorization was no longer appropriate. This action was taken following a rigorous assessment by scientists in the Center for Drug Evaluation and Research.
recently in this COVID 19 pandemic, the US President Donald Trump had urged India to export the hydroxychloroquine as the death toll in the US was increasing day by day. India is considered one of the important producers of these drugs which is considered as one of the important game-changer in the fight against corona.
Month: Current Affairs - June, 2020